Most Read Articles
Naomi Rodrig, one year ago
Third-generation EGFR tyrosine kinase inhibitors (TKIs) designed to overcome the T790M mutation have been shown to double progression-free survival (PFS) of patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations, according to reports at the European Lung Cancer Conference (ELCC) 2016 held recently in Geneva, Switzerland.
Joy Wee, one year ago
Symptomatic rhinovirus (RV) infections in infants are associated with a decrease in bacterial diversity and higher bacterial density of the respiratory microbiota.
one year ago
Umeclidinium/vilanterol improves SGRQ total score and decreased rescue albuterol use in patients with chronic obstructive pulmonary disease (COPD), as observed in a 12-week multicentre, randomised, double-blind, parallel-group, placebo-controlled study.
one year ago
Fluticasone furoate-vilanterol combination increases trough forced expiratory volume in 1 second compared with fluticasone furoate-fluticasone propionate in patients with symptomatic asthma, as stated in a systemic review with meta-analysis of seven published randomised clinical trials.

New Product Highlight - Flutiform

one year ago
FLUTIFORM®– Fluticasone propionate and Formoterol fumarate Inhalation 50 mcg/5 mcg, 125 mcg/5 mcg and 250 mcg/10 mcg  
• flutiform® combines the ICS and LABA that doctors prefer:1,2
     - Well-tolerated and potent anti-inflammatory effects of fluticasone1-5
     - Fast onset and sustained bronchodilatory action of formoterol1-5
• flutiform® delivers a consistently high fine particle fraction across flow rates.6

References:
1. Price D, Bousquet J. Real-world perceptions of inhaled corticosteroid/long-acting β2-agonist combinations in the treatment of asthma. Resp Med 2012; 106 (S1): S4-S8.
2.
Thomas M, Haughney J, Price D. Physicians’ attitudes towards combination therapy with inhaled corticosteroids and long-acting β2-agonist: an observational study in UK specialist care. Prag Obs Res 2011; 2: 25-31.
3. Flutiform® Approved Prescribing Information/Data Sheet.
4. Bodzenta-Lukaszyk A et al. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatmentof asthma, but has a more rapid onset of action: an open-label, randomized study. BMC Pulm Med 2011; 11: 28-37.
5. Aalbers R et al. Onset ofbronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study. Adv Ther 2012; 29 (11):958-969.
6.
Johal B, Howald M, Fischer M, Marshall J. Comparison of the fine particle fraction of fluticasone propionate/formoterol fumarate combination with other combination products. Poster presented at the European Respiratory Society (ERS) 22nd Annual Congress, 1–5 September 2012, Vienna,Austria.

Further information available in Section 3b, New in This Issue and mims.com.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Naomi Rodrig, one year ago
Third-generation EGFR tyrosine kinase inhibitors (TKIs) designed to overcome the T790M mutation have been shown to double progression-free survival (PFS) of patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations, according to reports at the European Lung Cancer Conference (ELCC) 2016 held recently in Geneva, Switzerland.
Joy Wee, one year ago
Symptomatic rhinovirus (RV) infections in infants are associated with a decrease in bacterial diversity and higher bacterial density of the respiratory microbiota.
one year ago
Umeclidinium/vilanterol improves SGRQ total score and decreased rescue albuterol use in patients with chronic obstructive pulmonary disease (COPD), as observed in a 12-week multicentre, randomised, double-blind, parallel-group, placebo-controlled study.
one year ago
Fluticasone furoate-vilanterol combination increases trough forced expiratory volume in 1 second compared with fluticasone furoate-fluticasone propionate in patients with symptomatic asthma, as stated in a systemic review with meta-analysis of seven published randomised clinical trials.